@article {2254, title = {The Potential of Orthosiphon Aristatus Extract in Improving Skin Lesions in Atopic Dermatitis: A Mice Model Study}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {April 2024}, pages = {342-347}, type = {Research Article}, chapter = {342}, abstract = {

Introduction: This research discusses the potential of Orthosiphon aristatus, a medicinal plant, in improving skin lesions in Atopic Dermatitis by regulating Th2 cytokines and showing anti-allergic activity. Methods: The study was conducted using BALB/C mice induced with DNCB for 21 days to create an atopic dermatitis model. Then, the mice were orally administered Orthosiphon aristatus extract for 14 days (after 7 days of induction). The doses given were divided into six groups: 17.5 mg/kgbw, 35 mg/kgbw, 70 mg/kgbw, and 140 mg/kgbw. Molecular levels such as IgE, IL4, IL22, and PGE2 were analyzed from blood samples. In addition, the severity of skin lesions was assessed morphologically, and histological examination was performed to confirm clinical improvement. Results: This study showed that the administration of Orthosiphon aristatus extract reduced the severity of skin lesions in all intervention groups. Histologically, this extract reduced epidermal thickness and mast cell infiltration. These findings were also supported by dose-dependent decreases in IgE, IL4, IL22, and PGE2 levels. So, the conclusion of this study is that Orthosiphon aristatus extract shows potential for improving skin lesions in atopic dermatitis by regulating Th2 cytokines and demonstrating anti-allergic activity in a mice model with DNCBinduced atopic dermatitis. Conclusion:\ The administration of Orthosiphon aristatus extract clinically and histologically exhibits anti-atopic effects that can be explained through the regulation of molecules such as IgE, IL4, IL22, PGE2, and NO. Orthosiphon aristatus has the potential to be a valuable herbal therapy for managing atopic dermatitis.

}, keywords = {Atopic dermatitis, Orthosiphon aristatus, Skin lesions, Th2 cytokines}, doi = {10.5530/pj.2024.16.52}, author = {Thigita Aga Pandaleke and Kusworini Handono and Dhelya Widasmara and Hani Susianti} } @article {2015, title = {Analysis of the Metabolite Compound of the Ethanol Extract of Chrysanthemum cinerariifolium Stem and Activity for inhibition of Oral Squamous Cell Carcinoma (OSCC) in silico study}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {April 2023}, pages = {393-398}, type = {Research Article}, chapter = {393}, abstract = {

Background: Oral cancer is a deadly disease that is expected to increase yearly. Current cancer treatment methods have side effects. C. cinerariifolium plants have potential as anticancer agents. Objective: To evaluate the anti-OSCC properties of the ethanol extract of C. cinerariifolium stems via an in-silico study. Materials and Methods: Analysis of active compounds in ethanol extracts of C. cinerariifolium stems using TLC and UPLC-QToF-MS/MS metabolic profiling. The data were analysed statistically using principal component analysis (PCA). In silico of C. cinerariifolium compounds on protein (PI3K and Cyclin D) from OSCC. Results: TLC procedures utilizing UV light with λ 366 nm after spraying with H2SO4 revealed multiple-colored spots, indicating that H2SO4 is a specific spray detector for terpenoid and carotene. Metabolic profiling in ethanol extract of C. cinerariifolium stem included Pronethalol (3.96\%), 1-(4-Methoxyphenyl)-N-(1 naphthylmethyl) methanamine (7.34\%), Orphenadrine (24.27\%), Pentazocine (5.09\%), 4-(Dodecyloxy) aniline (6.30\%), Linoleamide (4.95\%), and Pheophorbide A (8.05\%). Orphenadrine had the highest percentage. Based on the Lipinski rule of five, pronethalol has the potential to be used as a drug-like therapy for OSCC. The anticancer activity profile is predicted by PASS online with a likely range of 0.065 to 0.385. An in-silico study showed that the strongest binding affinity is pronethalol to Cyclin D1 and pheophorbide A to the PI3K protein. Conclusion: The active metabolite of the ethanolic extract of C. cinerariifolium stem exhibits potency against oral squamous cell carcinoma via the downregulation of the cell cycle (cyclin D1) and P13K, especially pronethalol.

}, keywords = {Chrysanthemum cinerariifolium, Cyclin D1, OSCC, P13K.}, doi = {10.5530/pj.2023.15.61}, author = {Anik Listiyana and Yuanita Lely Rachmawati and Hani Susianti and Nurdiana and Hidayat Sujuti and Roihatul Mutiah and Agustina Tri Endharti} }